logo-loader
viewZelira Therapeutics Ltd

Zelira Therapeutics in discussions to license medicinal cannabis products in US

The company released interim results of an Insomnia Clinical Trial during the quarter, the first in the world to have a primary endpoint assessing the impact of a full-spectrum cannabis extract on sleep.

Zelira Therapeutics Ltd - Zelira Therapeutics in discussions with third parties to licence medicinal cannabis products in US
Zelira ended the March quarter with A$4.02 million cash in bank

Zelira Therapeutics Ltd (ASX:ZLD) (OTCMKTS:ZLDAF) is in discussions with third parties to license products in the US and secure agreements for distribution in emerging global medicinal cannabis markets including Australia, Germany and the United Kingdom.

In its March quarterly report, the company highlighted concluding the quarter with a cash position of A$4.02 million after completing a placement to raise more than A$4.64 million.

These funds will be used to accelerate Zelira’s plans to launch multiple products into global markets in the second half of 2020 as well as progressing clinical programs such as its Insomnia and Opioid Sparing trials.   

The medicinal cannabis company also received its maiden revenues from Advanced Biomedics for its fist licensing deal for Hope™, which is anticipated to launch later in 2020.

Insomnia Clinical Trial (Perth)

From an operational standpoint, the company released interim results of its Insomnia Clinical Trial during the quarter having met its primary endpoints for efficacy and safety.

Results confirmed the ZLT-101 therapy achieved the primary endpoint of a statistically significant improvement in Insomnia Severity Index scores, a gold-standard measure of insomnia severity, in patients diagnosed with chronic insomnia compared to placebo.

A complementary pharmacokinetic (PK) sub-study was also initiated in the same patient cohort to provide important insights into the absorption of ZTL-101 following oral delivery.

Data from the PK sub-study and the final report for ZTL-101 will form the most comprehensive clinical data-pack for the use of medicinal cannabis to treat chronic insomnia.

Opiod Reduction Study (Melbourne)

Zelira is undertaking a study in collaboration with St Vincent’s Hospital in Melbourne to assess the safety and effectiveness of medicinal cannabis to reduce opioid dependence.

During the quarter, Emerald Clinics were engaged as a second site and the trial reached full enrolment with all patients subsequently completing dosing by early April 2020.

No serious adverse events have been reported to date and the company is on track to provide a final report in the current quarter.

Collaboration with US Parkinson’s Foundation

In January, the company entered into a collaboration with the Parkinson’s Foundation to gather insights from people with PD about their understanding of and use of medical cannabis and hemp-derived therapies.

Separately, Zelira will use survey insights in the future development of clinically validated medical cannabis for people with Parkinson’s disease.

It is aiming to launch its first product for Parkinson’s disease in the second half of 2020.

Quick facts: Zelira Therapeutics Ltd

Price: 0.053 AUD

ASX:ZLD
Market: ASX
Market Cap: $51.21 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zelira Therapeutics Ltd named herein, including the promotion by the Company of Zelira Therapeutics Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Zelira Therapeutics releases interim data for Phase II...

Zelira Therapeutics Ltd (ASX:ZLD) managing director Dr Richard Hopkins, chairman Osagie Imasogie and clinical trial principal investigator Professor Peter Eastwood, of the University of Western Australia, update Proactive on results from the company’s Phase II clinical trial of medicinal...

on 21/2/20

2 min read